A Phase 2 Trial of Radium223 and Stereotactic Ablative Radiotherapy in Hormone-Naïve Men with Oligometastatic Prostate Cancer to Bone: The RadSABR study
{{output}}
Purpose: We hypothesized that treatment with Radium223 (Ra223) and Stereotactic Ablative Radiotherapy (SABR) in patients with bone-only metachronous oligometastastic hormone-sensitive prostate cancer (moHSPC) could safely delay t... ...
